Bacterial Vaginosis and Subclinical Markers of Genital Tract Inflammation and Mucosal Immunity

AIDS Research and Human Retroviruses

Volumn 31, Issue 11, 2015, Pages 1139-1152

  Thurman, Andrea Ries ^a   Kimble, Thomas ^a   Herold, Betsy ^b   Mesquita, Pedro M M ^b   Fichorova, Raina N ^c   Dawood, Hassan Y ^c   Fashemi, Titilayo ^c   Chandra, Neelima ^a   Rabe, Lorna ^d   Cunningham, Tina D ^a   Anderson, Sharon ^a   Schwartz, Jill ^a   Doncel, Gustavo ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR5; GROWTH RELATED ONCOGENE ALPHA; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; METRONIDAZOLE; PROTEIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER;

ADULT; ARTICLE; CD4 CD8 RATIO; CLINICAL ARTICLE; COHORT ANALYSIS; CONTRACEPTIVE BEHAVIOR; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; GENITAL TRACT INFLAMMATION; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; LONGITUDINAL STUDY; LUTEAL PHASE; MUCOSAL IMMUNITY; OPEN STUDY; PRIORITY JOURNAL; SEXUAL PRACTICE; VAGINA DISCHARGE; VAGINA EPITHELIUM; VAGINA FLORA; VAGINITIS; ASYMPTOMATIC INFECTION; BIOPSY; INFLAMMATION; MICROBIOLOGY; PATHOLOGY; REPRODUCTIVE TRACT INFECTIONS; UTERINE CERVIX; VAGINA; VAGINAL LAVAGE; VAGINOSIS, BACTERIAL;

ADULT; ANTI-INFECTIVE AGENTS; ASYMPTOMATIC INFECTIONS; BIOMARKERS; BIOPSY; CERVIX UTERI; FEMALE; HUMANS; IMMUNITY, MUCOSAL; INFLAMMATION; LONGITUDINAL STUDIES; METRONIDAZOLE; REPRODUCTIVE TRACT INFECTIONS; VAGINA; VAGINAL DOUCHING; VAGINOSIS, BACTERIAL;

EID: 84946724560     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2015.0006     Document Type: Article

References (89)

1. Koumans EH, Sternberg M, Bruce C, et al. : The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis 2007;34(11):864-869.
2. Allsworth JE and Peipert JF: Prevalence of bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data. Obstet Gynecol 2007;109(1):114-120.
3. Johnson LF, Coetzee DJ, and Dorrington RE: Sentinel surveillance of sexually transmitted infections in South Africa: A review. Sex Transm Infect 2005;81(4):287-293.
4. Kenyon C, Colebunders R, and Crucitti T: The global epidemiology of bacterial vaginosis: A systematic review. Am J Obstet Gynecol 2013;209(6):505-523.
5. Bradshaw CS, Morton AN, Hocking J, et al. : High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006;193(11):1478-1486.
6. UNAIDS WHO: 09 AIDS Epidemic Update. 2009; http:// data. unaids. org/pub/Report/2009/JC1700-Epi-Update-2009 -en. pdf Accessed July 15, 2010.
7. Royce RA, Thorp J, Granados JL, and Savitz DA: Bacterial vaginosis associated with HIV infection in pregnant women from North Carolina. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20(4):382-386.
8. Cohen CR, Duerr A, Pruithithada N, et al. : Bacterial vaginosis and HIV seroprevalence among female commercial sex workers inChiangMai,Thailand. AIDS 1995;9(9):1093-1097.
9. Sewankambo N, Gray RH, Wawer MJ, et al. : HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet 1997;350(9077):546-550.
10. Hillier SL: The vaginal microbial ecosystem and resistance to HIV. AIDS Res HumRetroviruses 1998;14(Suppl 1):S17-21.
11. van De Wijgert JH, Mason PR, Gwanzura L, et al. : Intravaginal practices, vaginal flora disturbances, and acquisition of sexually transmitted diseases in Zimbabwean women. J Infect Dis 2000;181(2):587-594.
12. Martin HL, Richardson BA, Nyange PM, et al. : Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis 1999;180(6):1863-1868.
13. Taha TE, Hoover DR, Dallabetta GA, et al. : Bacterial vaginosis and disturbances of vaginal flora: Association with increased acquisition of HIV. AIDS 1998;12(13):1699-1706.
14. Myer L, Denny L, Telerant R, et al. : Bacterial vaginosis and susceptibility to HIV infection in South African women: A nested case-control study. J Infect Dis 2005;192(8): 1372-1380.
15. van de Wijgert JH, Morrison CS, Brown J, et al. : Disentangling contributions of reproductive tract infections to HIV acquisition in African women. Sex Transm Dis 2009;36(6):357-364.
16. van de Wijgert JH, Morrison CS, Cornelisse PG, et al. : Bacterial vaginosis and vaginal yeast, but not vaginal cleansing, increase HIV-1 acquisition in African women. J Acquir Immune Defic Syndr 2008;48(2):203-210.
17. Cohen CR, Lingappa JR, Baeten JM, et al. : Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: A prospective cohort analysis among African couples. PLoS Med 2012;9(6):e1001251.
18. Grosskurth H, Mosha F, Todd J, et al. : Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: Randomised controlled trial. Lancet 1995;346(8974):530-536.
19. Hayes R, Mosha F, Nicoll A, et al. : A community trial of the impact of improved sexually transmitted disease treatment on the HIV epidemic in rural Tanzania: 1. Design. AIDS 1995;9(8):919-926.
20. Wawer MJ, Sewankambo NK, Serwadda D, et al. : Control of sexually transmitted diseases for AIDS prevention in Uganda: A randomised community trial. Rakai Project Study Group. Lancet 1999;353(9152):525-535.
21. Mirmonsef P, Krass L, Landay A, and Spear GT: The role of bacterial vaginosis andTrichomonas inHIVtransmission across the female genital tract. Curr HIV Res 2012;10(3):202-210.
22. Thurman AR and Doncel GF: Innate immunity and inflammatory response to Trichomonas vaginalis and bacterial vaginosis: Relationship to HIV acquisition. Am J Reprod Immunol 2011;65(2):89-98.
23. Nugent RP, Krohn MA, and Hillier SL: Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991;29(2):297-301.
24. Venkataraman N, Cole AL, Svoboda P, et al. : Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J Immunol 2005;175(11):7560-7567.
25. Venkataraman N, Cole AL, Ruchala P, et al. : Reawakening retrocyclins: Ancestral human defensins active against HIV-1. PLoS Biol 2009;7(4):e95.
26. Ghosh M, Fahey JV, Shen Z, et al. : Anti-HIV activity in cervical-vaginal secretions from HIV-positive and-negative women correlate with innate antimicrobial levels and IgG antibodies. PLoS One 2010;5(6):e11366.
27. Ghosh M, Shen Z, Fahey JV, et al. : Trappin-2/Elafin: A novel innate anti-human immunodeficiency virus-1 molecule of the human female reproductive tract. Immunology 2010;129(2):207-219.
28. Madan RP, Carpenter C, Fiedler T, et al. : Altered biomarkers of mucosal immunity and reduced vaginal Lactobacillus concentrations in sexually active female adolescents. PLoS One 2012;7(7):e40415.
29. Kalyoussef S, Nieves E, Dinerman E, et al. : Lactobacillus proteins are associatedwith the bactericidal activity against E. coli of female genital tract secretions. PLoS One 2012;7(11): e49506.
30. Gajer P,BrotmanRM,Bai G, et al. : Temporal dynamics of the human vaginal microbiota. Sci Transl Med 2012;4(132): 132ra152.
31. Murray PR and Jorgensen JH: Manual of Clinical Microbiology, Vol. 9. ASM Press, Washington, DC, 2007.
32. Gentry YM, Hillier SL, and Eschenbach DA: Evaluation of a rapid enzyme immunoassay test for detection of group B Streptococcus. Obstet Gynecol 1991;78(3 Pt 1):397-401.
33. Rabe LK and Hillier SL: Optimization of media for detection of hydrogen peroxide production by Lactobacillus species. J Clin Microbiol 2003;41(7):3260-3264.
34. Keller MJ, Madan RP, Torres NM, et al. : A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One 2011;6(1):e16475.
35. Choe H, Farzan M, Sun Y, et al. : The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85(7):1135-1148.
36. Hladik F, Sakchalathorn P, Ballweber L, et al. : Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 2007;26(2):257-270.
37. Deng H, Liu R, Ellmeier W, et al. : Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381(6584):661-666.
38. Rebbapragada A, Howe K, Wachihi C, et al. : Bacterial vaginosis in HIV-infected women induces reversible alterations in the cervical immune environment. J Acquir Immune Defic Syndr 2008;49(5):520-522.
39. Giraldo PC, de Carvalho JB, do Amaral RL, et al. : Identification of immune cells by flow cytometry in vaginal lavages from women with vulvovaginitis and normal microflora. Am J Reprod Immunol 2012;67(3):198-205.
40. Sobel JD: Vulvovaginal candidosis. Lancet 2007;369(9577): 1961-1971.
41. Saba E, Grivel JC, Vanpouille C, et al. : HIV-1 sexual transmission: Early events of HIV-1 infection of human cervico-vaginal tissue in an optimized ex vivo model. Mucosal Immunol 2010;3(3):280-290.
42. Gebhardt T, Whitney PG, Zaid A, et al. : Different patterns of peripheral migration by memory CD4 + and CD8 + T cells. Nature 2011;477(7363):216-219.
43. Mackay LK, Stock AT, Ma JZ, et al. : Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc Natl Acad Sci USA 2012;109:7037-7042.
44. Musey L, Hu Y, Eckert L, et al. : HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women. J Exp Med 1997;185(2):293-303.
45. Jiang J and Kelly KA: Phenotype and function of regulatory T cells in the genital tract. CurrTrends Immunol 2011;12:89-94.
46. Peipert JF, Lapane KL, Allsworth JE, et al. : Bacterial vaginosis, race, and sexually transmitted infections: Does race modify the association? Sex TransmDis 2008;35(4):363-367.
47. Cherpes TL, Hillier SL, Meyn LA, et al. : A delicate balance: Risk factors for acquisition of bacterial vaginosis include sexual activity, absence of hydrogen peroxide-producing lactobacilli, black race, and positive herpes simplex virus type 2 serology. Sex Transm Dis 2008;35(1):78-83.
48. Ravel J, Gajer P, Abdo Z, et al. : Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA 2012;108(Suppl 1):4680-4687.
49. Odendaal HJ, Popov I, Schoeman J, et al. : Preterm labour- is bacterial vaginosis involved? S Afr Med J 2002;92(3): 231-234.
50. Klebanoff MA, Carey JC, Hauth JC, et al. : Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001;345(7):487-493.
51. Valore EV, Wiley DJ, and Ganz T: Reversible deficiency of antimicrobial polypeptides in bacterial vaginosis. Infect Immun 2006;74(10):5693-5702.
52. Cauci S, Guaschino S, De Aloysio D, et al. : Interrelationships of interleukin-8 with interleukin-1beta and neutrophils in vaginal fluid of healthy and bacterial vaginosis positive women. Mol Hum Reprod 2003;9(1):53-58.
53. Sturm-Ramirez K, Gaye-Diallo A, Eisen G, et al. : High levels of tumor necrosis factor-alpha and interleukin-1beta in bacterial vaginosis may increase susceptibility to human immunodeficiency virus. J Infect Dis 2000;182(2):467-473.
54. Cauci S, Culhane JF, Di Santolo M, and McCollum K: Among pregnant women with bacterial vaginosis, the hydrolytic enzymes sialidase and prolidase are positively associated with interleukin-1beta. Am J Obstet Gynecol 2008;198(1):e131-137.
55. Anton G, Rid J, Mylonas I, et al. : Evidence of a TH1-shift of local vaginal inflammatory response during bacterial vaginosis. Infection 2008;36(2):147-152.
56. Hemalatha R, Ramalaxmi BA, KrishnaSwetha G, et al. : Cervicovaginal inflammatory cytokines and sphingomyelinase in women with and without bacterial vaginosis. Am J Med Sci 2012;344(1):35-39.
57. Spandorfer SD, Neuer A, Giraldo PC, et al. : Relationship of abnormal vaginal flora, proinflammatory cytokines and idiopathic infertility in women undergoing IVF. J Reprod Med 2001;46(9):806-810.
58. Cauci S, Driussi S, Guaschino S, et al. : Correlation of local interleukin-1beta levels with specific IgA response against Gardnerella vaginalis cytolysin in women with bacterial vaginosis. Am J Reprod Immunol 2002;47(5):257-264.
59. Marconi C, Donders GG, Parada CM, et al. : Do Atopobium vaginae, Megasphaera sp. and Leptotrichia sp. change the local innate immune response and sialidase activity in bacterial vaginosis? Sex Transm Infect 2013;89(2):167-173.
60. Hedges SR, Barrientes F, Desmond RA, and Schwebke JR: Local and systemic cytokine levels in relation to changes in vaginal flora. J Infect Dis 2006;193(4):556-562.
61. Al-Harthi L, Spear GT, Hashemi FB, et al. : A human immunodeficiency virus (HIV)-inducing factor from the female genital tract activates HIV-1 gene expression through the kappaB enhancer. J Infect Dis 1998;178(5):1343-1351.
62. Spear GT, al-Harthi L, Sha B, et al. : A potent activator of HIV-1 replication is present in the genital tract of a subset of HIV-1-infected and uninfected women. AIDS 1997;11(11): 1319-1326.
63. Olinger GG, Hashemi FB, Sha BE, and Spear GT: Association of indicators of bacterial vaginosis with a female genital tract factor that induces expression of HIV-1. AIDS 1999;13(14):1905-1912.
64. Al-Harthi L, Roebuck KA, Olinger GG, et al. : Bacterial vaginosis-associated microflora isolated from the female genital tract activates HIV-1 expression. J. Acquir. Immune Defic. Syndr 1999;21(3):194-202.
65. Hashemi FB, Ghassemi M, Roebuck KA, and Spear GT: Activation of human immunodeficiency virus type 1 expression by Gardnerella vaginalis. J Infect Dis 1999;179(4): 924-930.
66. Osborn L, Kunkel S, and Nabel GJ: Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci USA 1989;86(7):2336-2340.
67. Mauck CK, Lai JJ, Weiner DH, et al. : Toward early safety alert endpoints: Exploring biomarkers suggestive of microbicide failure. AIDS Res Hum Retroviruses 2013;29(11): 1475-1486.
68. Taylor BD, Holzman CB, Fichorova RN, et al. : Inflammation biomarkers in vaginal fluid and preterm delivery. Hum Reproduct 2013;28(4):942-952.
69. Youn H, Hong K, Yoo JW, and Lee CH: ICAM-1 expression in vaginal cells as a potential biomarker for inflammatory response. Biomarkers 2008;13(3):257-269.
70. TaguchiM, Sampath D, Koga T, et al. : Patterns for RANTES secretion and intercellular adhesion molecule 1 expression mediate transepithelial T cell traffic based on analyses in vitro and in vivo. J Exp Med 1998;187(12):1927-1940.
71. Pearce-Pratt R and Phillips DM: Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1. Biol Reprod 1996;54(1):173-182.
72. Fichorova RN, Desai PJ, Gibson FC 3rd, and Genco CA: Distinct proinflammatory host responses to Neisseria gonorrhoeae infection in immortalized human cervical and vaginal epithelial cells. Infect Immun 2001;69(9):5840-5848.
73. Fichorova RN and Anderson DJ: Differential expression of immunobiological mediators by immortalized human cervical and vaginal epithelial cells. Biol Reprod 1999;60(2): 508-514.
74. Fichorova RN, Lee Y, Yamamoto HS, et al. : Endobiont viruses sensed by the human host-beyond conventional antiparasitic therapy. PloS One 2012;7(11):e48418.
75. Chancey CJ, Khanna KV, Seegers JF, et al. : Lactobacilliexpressed single-chain variable fragment (scFv) specific for intercellular adhesion molecule 1 (ICAM-1) blocks cellassociated HIV-1 transmission across a cervical epithelial monolayer. J Immunol 2006;176(9):5627-5636.
76. de Jong MA, de Witte L, Oudhoff MJ, et al. : TNF-alpha and TLR agonists increase susceptibility to HIV-1 transmission by human Langerhans cells ex vivo. J Clin Invest 2008;118(10):3440-3452.
77. Balkus J, Agnew K, Lawler R, et al. : Effects of pregnancy and bacterial vaginosis on proinflammatory cytokine and secretory leukocyte protease inhibitor concentrations in vaginal secretions. J Pregnancy 2010;2010:385981.
78. Mitchell C, Balkus J, Agnew K, et al. : Changes in the vaginal microenvironment with metronidazole treatment for bacterial vaginosis in early pregnancy. J Womens Health (Larchmt) 2009;18(11):1817-1824.
79. Mitchell CM, Balkus J, Agnew KJ, et al. : Bacterial vaginosis, not HIV, is primarily responsible for increased vaginal concentrations of proinflammatory cytokines. AIDS Res Hum Retroviruses 2008;24(5):667-671.
80. Novak RM, Donoval BA, Graham PJ, et al. : Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Clin Vaccine Immunol 2007;14(9):1102-1107.
81. Draper DL, Landers DV, Krohn MA, et al. : Levels of vaginal secretory leukocyte protease inhibitor are decreased in women with lower reproductive tract infections. Am J Obstet Gynecol 2000;183(5):1243-1248.
82. Morrison C, Fichorova RN, Mauck C, et al. : Cervical inflammation and immunity associated with hormonal contraception, pregnancy, and HIV-1 seroconversion. J Acquir Immune Defic Syndr 2014;66(2):109-117.
83. Adams DH and Lloyd AR: Chemokines: Leucocyte recruitment and activation cytokines. Lancet 1997;349(9050): 490-495.
84. Shust GF, Cho S, Kim M, et al. : Female genital tract secretions inhibit herpes simplex virus infection: Correlation with soluble mucosal immune mediators and impact of hormonal contraception. Am J Reprod Immunol 2010;63(2): 110-119.
85. Valore EV, Park CH, Igreti SL, and Ganz T: Antimicrobial components of vaginal fluid. AmJ Obstet Gynecol 2002;187(3): 561-568.
86. YudinMH, LandersDV, Meyn L, andHillier SL:Clinical and cervical cytokine response to treatment with oral or vaginal metronidazole for bacterial vaginosis during pregnancy: A randomized trial. Obstet Gynecol 2003;102(3):527-534.
87. Losikoff P, Fichorova R, Snyder B, et al. : Genital tract interleukin-8 but not interleukin-1beta or interleukin-6 concentration is associated with bacterial vaginosis and its clearance in HIV-infected and HIV-uninfected women. Infect Dis Obstet Gynecol 2007;2007:92307.
88. Cherpes TL, Marrazzo JM, Cosentino LA, et al. : Hormonal contraceptive use modulates the local inflammatory response to bacterial vaginosis. Sex Transm Infect 2008;84(1):57-61.
89. Ryckman KK, Williams SM, Krohn MA, and Simhan HN: Racial differences in cervical cytokine concentrations between pregnant women with and without bacterial vaginosis. J Reprod Immunol 2008;78(2):166-171.